Lupus anticoagulant in cardiovascular diseases: The role of β2-glycoprotein I

Annals of Medicine

Volumn 32, Issue SUPPL. 1, 2000, Pages 32-36

  De Groot, P G ^a   Bouma, B ^a   Lutters, B C H ^a   Derksen, R H W M ^a  

^a Department of Haematology   (Netherlands)

Author keywords

2 glycoprotein I; Antiphospholipid antibodies; Lupus anticoagulant; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

CARDIOVASCULAR DISEASE; COMPLEX FORMATION; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ANTIBODIES, ANTICARDIOLIPIN; BETA 2-GLYCOPROTEIN I; CARDIOVASCULAR DISEASES; EPITOPES; GLYCOPROTEINS; HUMANS; LUPUS COAGULATION INHIBITOR; MEMBRANE GLYCOPROTEINS; THROMBOSIS;

EID: 0034511622     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Antiphospholipid antibodies and thrombosis
2. 2-glycoprotein I
3. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor
4. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
5. Role of divalency in the high affinity binding of cardiolipin antibody-beta2-glycoprotein I complexes to lipid membranes
6. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody-beta2-glycoprotein I complexes on phospholipid surfaces
7. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus
8. Kaolin clotting time and dilute Russel Vipor Venom Time distinguish between prothrombin dependent and beta2-glycoprotein I dependent anti phospholipid antibodies
9. The contribution of experimental models to our understanding of etiology, pathogenesis and novel therapies in the antiphospholipid syndrome
10. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I
11. Lupus anticoagulants: Mechanistic and diagnostic considerations
12. Antiphospholipid antibodies: Specificity and pathophysiology
13. The pathogenesis of the antiphospholipid syndrome: A hypothesis based on parallelisms with heparin induced thrombocytopenia
14. Anticardiolipid subclasses. Association with IgG2 with arterial and/or venous thrombosis
15. Vasculopathy of the antiphospholipid syndrome revisited: Thrombosis is the culprit and vasculitis the consort
16. 2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis
17. 2-glycoprotein I
18. 2-glycoprotein I
19. 2-glycoprotein I: Influence in the triglyceride metabolism in the rat
20. 2-glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway
21. 2-glycoprotein I in macrophage recognition
22. 2-glycoprotein I deficiency and the risk of thrombosis
23. Adhesion mechanism of human beta2-glycoprotein I to phospholipids based on its crystal structure
24. Crystal structure of human beta2-glycoprotein I: Implications for phospholipid binding and the antiphospholipid syndrome
25. 2-glycoprotein I) is crucial for cardiolipin binding
26. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI
27. 2-glycoprotein I-phospholpid complexes harbor a recognition site for the endocytotic receptor megalin
28. 2-glycoproteine I: Use as reference material for lupus anticoagulant tests
29. Prevention of experimental aPL syndrome and endothelial cell activation by synthetic peptides
30. GDKV-induced aPL Abs enhance thrombosis and activate endothelial cells in vivo and in vitro
31. Membrane induced conformational changes in human apolipiprotein H
32. 2-glycoprotein I-anti-beta2-glycoprotein I antibody complexes